# Evgen Pharma plc To hold Investor Symposium on the clinical significance of SFX-01

- Link: https://www.directorstalkinterviews.com/evgen-pharma-plc-to-hold-investor-symposium-on-the-clinical-significance-of-sfx-01/412758271
- Published: 2018-09-11T07:14:25+01:00
- Author: Giles Arbor

**Evgen Pharma plc** (LON:EVG), a clinical stage drug development company focused
on the treatment of cancer and neurological conditions, have announced today that
it is to hold an Investor Symposium for investors and analysts on the morning of
Tuesday 18 September 2018.

The Investor Symposium, titled “The clinical significance of SFX-01”, will be an
opportunity to engage with the Company and independent experts to help frame the
significance of the two Phase II clinical read-outs of SFX-01 expected around the
end of the year.

The morning will feature a short introduction by Evgen’s CEO, Stephen Franklin, 
followed by a series of presentations and a Q&A session. The presentations will 
include:

• Vadim Alexandre – Managing Director, Northland Capital Partners
 The biotech investment
market and Evgen Pharma plc

• Prof Albena Dinkova-Kostova – University of Dundee
 The science behind sulforaphane

• Dr Sasha Howell – The Christie Hospital, Manchester
 The STEM trial in breast 
cancer

• Sally Ross – Clinical Development Officer, Evgen
 The SAS trial in haemorrhagic
stroke and the preclinical pipeline

The event will be held at the offices of Buchanan, 107 Cheapside, London EC2V 6DN
and will begin at 9.15am. The presentations will be available on the Evgen Pharma
plc website on the day. No new material trading information will be disclosed.

Those interested in attending the event, can register with Buchanan on 020 7466 
5000 or email tillya@buchanan.uk.com

Share on: